CN113891944A - Kit for detecting pathogen RNA, animal or human gene RNA and application thereof - Google Patents
Kit for detecting pathogen RNA, animal or human gene RNA and application thereof Download PDFInfo
- Publication number
- CN113891944A CN113891944A CN202180001625.8A CN202180001625A CN113891944A CN 113891944 A CN113891944 A CN 113891944A CN 202180001625 A CN202180001625 A CN 202180001625A CN 113891944 A CN113891944 A CN 113891944A
- Authority
- CN
- China
- Prior art keywords
- rna
- gene
- detecting
- cov
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 149
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 39
- 244000052769 pathogen Species 0.000 title claims abstract description 37
- 230000001717 pathogenic effect Effects 0.000 title claims abstract description 33
- 241001465754 Metazoa Species 0.000 title claims abstract description 23
- 238000001514 detection method Methods 0.000 claims abstract description 89
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 83
- 238000006243 chemical reaction Methods 0.000 claims abstract description 59
- 241000711573 Coronaviridae Species 0.000 claims abstract description 35
- 239000000523 sample Substances 0.000 claims description 96
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 90
- 150000007523 nucleic acids Chemical group 0.000 claims description 36
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 108700002099 Coronavirus Nucleocapsid Proteins Proteins 0.000 claims description 6
- 108700039887 Essential Genes Proteins 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 241000606161 Chlamydia Species 0.000 claims description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
- 241000204031 Mycoplasma Species 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 241000606701 Rickettsia Species 0.000 claims description 2
- 241000589970 Spirochaetales Species 0.000 claims description 2
- 208000016361 genetic disease Diseases 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 46
- 230000035945 sensitivity Effects 0.000 abstract description 19
- 238000003908 quality control method Methods 0.000 abstract description 5
- 238000002955 isolation Methods 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 239000012634 fragment Substances 0.000 abstract 1
- 108090000621 Ribonuclease P Proteins 0.000 description 43
- 102000039446 nucleic acids Human genes 0.000 description 30
- 108020004707 nucleic acids Proteins 0.000 description 30
- 238000003753 real-time PCR Methods 0.000 description 30
- 230000003321 amplification Effects 0.000 description 25
- 238000003199 nucleic acid amplification method Methods 0.000 description 25
- 241001112090 Pseudovirus Species 0.000 description 17
- 238000005516 engineering process Methods 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 14
- 229940069446 magnesium acetate Drugs 0.000 description 14
- 235000011285 magnesium acetate Nutrition 0.000 description 14
- 239000011654 magnesium acetate Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 210000000601 blood cell Anatomy 0.000 description 12
- 208000025721 COVID-19 Diseases 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 102000018120 Recombinases Human genes 0.000 description 10
- 108010091086 Recombinases Proteins 0.000 description 10
- 206010035664 Pneumonia Diseases 0.000 description 8
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 8
- 230000035484 reaction time Effects 0.000 description 8
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 7
- 101710116602 DNA-Binding protein G5P Proteins 0.000 description 7
- 101710162453 Replication factor A Proteins 0.000 description 7
- 101710176758 Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 description 7
- 101710176276 SSB protein Proteins 0.000 description 7
- 101710126859 Single-stranded DNA-binding protein Proteins 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000013614 RNA sample Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102100034343 Integrase Human genes 0.000 description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000003161 ribonuclease inhibitor Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108060002716 Exonuclease Proteins 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 102000004167 Ribonuclease P Human genes 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000011330 nucleic acid test Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 2
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 2
- 102100024407 Jouberin Human genes 0.000 description 2
- 101150068419 ORF 1 gene Proteins 0.000 description 2
- 101100240079 Severe acute respiratory syndrome coronavirus 2 N gene Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 101150013191 E gene Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036438 mutation frequency Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6848—Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a kit for detecting pathogen RNA and animal or human gene RNA, which comprises a primer pair for detecting the pathogen RNA and the animal or human gene RNA by using RT-nested RPA and a primer pair for detecting an internal reference gene by using RT-nested RPA, wherein the primer pair for detecting the pathogen RNA and the animal or human gene RNA and the primer pair for detecting the internal reference gene simultaneously carry out detection reaction in the same reaction tube. The kit for detecting the RNA of the pathogen and the RNA of the animal or human gene realizes the simultaneous detection of the RNA level of the target gene and the reference gene of the pathogen, increases the quality control of the reference gene on the experimental process, and avoids false negative results. Moreover, the kit for detecting the new coronavirus can detect the SARS-CoV-2 virus RNA fragment of 1 copy/uL at the lowest, has ultrahigh sensitivity, provides new technical support for early discovery, early isolation and early treatment of the new coronavirus SARS-CoV-2, and has very good application prospect.
Description
Technical Field
The invention belongs to the technical field of biological engineering, and particularly relates to a kit for detecting pathogens based on an RT-nested RPA (RT-nestRPA) technology and application thereof.
Background
Since the end of 12 months in 2019, a large-scale epidemic of novel coronavirus infectious pneumonia (COVID-19) has emerged globally. COVID-19 is a global epidemic caused by infection with a novel coronavirus SARS-CoV-2. COVID-19 is characterized by long latent period, strong infectivity and high death rate. The epidemic is spread rapidly, and has caused huge harm to human health and great social and economic hazards.
Coronavirus (CoV), an enveloped single-stranded RNA virus, is widely transmitted in humans, and other mammals and birds, and can cause respiratory, intestinal, hepatic and nervous system diseases. 7 coronaviruses are known to cause disease in humans, 4 of which, such as Cov-229E, Cov-OC43, Cov-NL63 and Cov-HKU1, are prevalent in the human population and often cause common cold symptoms. In addition, the 3 coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2 are highly dangerous and can cause severe pneumonia and even death.
By 6 months and 8 days 2021, more than 1.73 million people have been diagnosed with new crown pneumonia (COVID-19) and the number of death cases reaches 373 ten thousand. At present, the work of preventing and controlling new coronary pneumonia in China is normalized, sporadic reports of cases in different cities are frequent, and the overseas input of case reports is continuous. At the same time, the epidemic in other countries around the world is still spreading continuously. The total confirmed cases in the United states, Brazil and India are far more than 1600 ten thousand. The survival chance of SARS-CoV-2 in environment is greatly increased, and the reports of detecting SARS-CoV-2 positive result by cold chain transportation staff, vehicles and even meat product samples are frequently available. In the new prevention and control measures of coronary pneumonia, early diagnosis and early treatment are the key. SARS-CoV-2 nucleic acid detection is an important means for quickly diagnosing new coronary pneumonia, and the nucleic acid detection method commonly used at present is fluorescence quantitative PCR (qPCR) technology. Based on the Chinese online data, 115 companies in China have developed 116 kits for detecting SARS-CoV-2 nucleic acid, 98 (84.5%) of which employ qPCR technology.
However, the nucleic acid detection technique of SARS-CoV-2 based on qPCR frequently results in "false negative" in clinical applications. Nucleic acid 'false negative' results based on a qPCR detection method are reported in sequence by a plurality of hospitals in China. Recent news shows that a positive nucleic acid result is obtained after 6 nucleic acid tests of patients, and before now, some patients are found to be negative after two nucleic acid tests of regular treatment, but the nucleic acid test results of the patients are positive again during isolation and observation. These false negative results greatly increase the complexity of the control of COVID-19 epidemics.
Viral nucleic acid testing, from the time a sample is taken from a patient to the completion of a test report, proceeds through a number of steps including sample collection, sample storage, sample transport to a testing laboratory, virus inactivation, cell lysis, nucleic acid extraction, testing and reporting of the test report. Any one of these steps may be somewhat problematic and may lead to false negative results. Wherein, the detection technology with high sensitivity, high specificity and high repeatability is very important for improving the detection quality of SARS-CoV-2 nucleic acid and reducing the false negative rate of experiments.
Recombinase Polymerase Amplification (RPA) is based on a Recombinase Polymerase-mediated Amplification principle, simulates an enzyme reaction process of in vivo DNA replication, depends on specific enzymes and protein combinations (Recombinase, single-stranded binding protein and DNA Polymerase) to perform specific Amplification on a DNA template, can realize rapid specific Amplification (37-42 ℃ for 5-30min) under the condition of approaching body temperature, is used as an isothermal technology to reduce the dependence on high-precision expensive instruments, stable power supply facilities and high-level laboratories, can be completed by only one thermostatic device, can judge whether Amplification products exist in real time by a fluorescence analysis device, has the characteristic of simpler facility and operation requirements, and is applied to multiple fields of life science research, medical detection, agriculture, food safety, transgenic detection and the like.
At present, an RT-RPA (reverse transcriptase-recombinase polymerase amplification) technology developed based on an RPA principle is available, namely reverse transcriptase and an RNase inhibitor are added in an RPA reaction system, so that an RNA nucleic acid sample can be rapidly amplified under a constant temperature condition, and the defect that the RNA sample can be detected only by reverse transcription into cDNA is overcome.
In the traditional RPA or RT-RPA detection, only 1 target gene is often detected in one reaction, and a new reaction is needed if an internal reference gene of a sample to be detected needs to be detected. This undoubtedly increases the time and economic costs of detection and increases the uncertainty of the interpretation of the results.
Although epidemic prevention work of vaccination against new coronavirus is vigorously popularized in various countries around the world at present, it still takes a long time to achieve complete population immunity. At present, the COVID-19 epidemic caused by SARS-CoV-2 virus is still spread continuously in a plurality of countries all over the world, the SARS-CoV-2 virus has stronger infectivity and faster propagation speed, and the epidemic is not effectively controlled. In addition, a plurality of cities in China have small-scale aggregated cases, and in 4 months this year, new crown epidemic situation is developed in the Reuli city in Yunnan province in China. Therefore, in order to realize effective prevention and control of the COVID-19 epidemic situation, a novel rapid nucleic acid detection technology with high sensitivity, high specificity and high repeatability is urgently needed to be developed.
Disclosure of Invention
The invention aims to solve the technical problem that a kit for quickly and accurately detecting pathogens such as SARS-CoV-2 new coronavirus and the like is lacked at present, and provides a kit for detecting pathogens based on an RT-nested RPA (RT-nestRPA) technology, wherein the kit simultaneously detects pathogen gene RNA and reference gene RNA by utilizing the RT-nestRPA technology, and can quickly, accurately, sensitively and specifically detect the pathogen RNA such as SARS-CoV-2 virus and the like.
In order to solve the technical problems, the invention is realized by the following technical scheme:
in one aspect of the invention, a kit for detecting pathogen RNA and animal or human gene RNA is provided, the kit comprises a primer pair for detecting pathogen RNA and animal or human gene RNA by RT-nested RPA and a primer pair for detecting internal reference gene RNA by RT-nested RPA, and the primer pair for detecting pathogen RNA and animal or human gene RNA and the primer pair for detecting internal reference gene RNA carry out detection reaction simultaneously in the same reaction tube.
Preferably, the pathogen RNA includes viral, bacterial, chlamydia, mycoplasma, rickettsia, spirochete, fungal, or parasitic RNA, and the animal or human gene RNA includes human tumor-associated gene mRNA and genetic disease-associated gene mRNA.
In a specific embodiment of the invention, the pathogen is SARS-CoV-2 new coronavirus, and the primer pair for detecting SARS-CoV-2 new coronavirus by RT-nested RPA is a primer pair directed to the nucleotide sequence shown in SEQ ID NO: 1 or a primer pair designed by the partial sequence of the N gene sequence of the SARS-CoV-2 new coronavirus. More preferably, the primer pair for detecting SARS-CoV-2 new coronavirus by RT-nested RPA comprises: SEQ ID NO: 3 and SEQ ID NO: 4, the sequence shown in SEQ ID NO: 5 and SEQ ID NO: 6.
Preferably, the reference gene is a human housekeeping gene, RP gene. The primer pair for detecting the RP gene by the RT-nested RPA comprises: SEQ ID NO: 9 and SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12.
Preferably, the kit further comprises a nucleic acid sequence specific for SEQ ID NO: 1 or partial sequence thereof, and a probe specifically designed for the N gene sequence of the SARS-CoV-2 new coronavirus or partial sequence thereof, wherein the probe is specifically designed for the N gene sequence of the SARS-CoV-2 new coronavirus or partial sequence thereof shown in SEQ ID NO: 7 or a partial sequence thereof.
In another aspect of the present invention, there is also provided a primer pair for detecting SARS-CoV-2 new coronavirus, which is a primer pair for detecting SARS-CoV-2 new coronavirus N gene in RT-nested RPA, comprising an outer primer pair and an inner primer pair.
Preferably, the primer pair is directed against SEQ ID NO: 1 or a partial sequence thereof, wherein the outer primer pair has the sequence shown in SEQ ID NO: 3 and SEQ ID NO: 4, and the inner primer pair has a nucleotide sequence shown as SEQ ID NO: 5 and SEQ ID NO: 6 in a sequence listing.
In another aspect of the present invention, there is also provided a probe for detecting SARS-CoV-2 novel coronavirus, which is a probe specific for the polypeptide of SEQ ID NO: 1 or partial sequence of N gene sequence of SARS-CoV-2 new coronavirus.
Preferably, the probe has the nucleotide sequence shown in SEQ ID NO: 2, or a nucleotide sequence shown in the figure.
In another aspect of the present invention, there is also provided a kit for detecting SARS-CoV-2 novel coronavirus, which comprises the above primer pair.
Preferably, the kit also comprises a primer pair for detecting the internal reference gene by using RT-nested RPA, and the primer pair for detecting the SARS-CoV-2 new coronavirus N gene and the primer pair for detecting the internal reference gene carry out detection reaction simultaneously in the same reaction tube.
The kit also comprises the probe and a probe specific to the reference gene.
In another aspect of the invention, the application of the kit in the preparation of products for detecting pathogens is also provided.
The kit for detecting the pathogen simultaneously carries out nucleic acid detection on the RNA of the pathogen and the RNA of the internal reference gene by an RT-nestRPA method, realizes the purpose of simultaneously detecting the target gene and the internal reference gene in the same tube, and ensures that the judgment of a detection result is more accurate. The kit for detecting the SARS-CoV-2 new coronavirus in the embodiment of the invention can detect 1 copy/uL of SARS-CoV-2 nucleic acid fragment at the lowest, has ultrahigh sensitivity, and the RT-nestRPA in the invention is carried out at the constant temperature of 39 ℃, does not need expensive detection equipment, has short detection time and only needs 15min, provides new technical support for early discovery, early isolation and early treatment of the new coronavirus SARS-CoV-2, and has very good application prospect.
Drawings
The present invention will be described in further detail with reference to the accompanying drawings and specific embodiments.
FIG. 1 is a SARS-CoV-2 genome mutation profile of example 1 of the present invention;
FIG. 2 is a graph showing the LOD results of the preferred primers for SARS-CoV-2N gene detection using RT-RPA in example 1 of the present invention;
FIG. 3 is a graph comparing the LOD results of SARS-CoV-2 pseudoviral RNA detection using RT-nestRPA in example 2 of the present invention;
FIG. 4 is a graph showing the results of screening for preferred primers for RP gene using RT-RPA method in example 3 of the present invention;
FIG. 5 is a graph showing comparison of the detection ability of RNA RP gene in human blood cells by RT-RPA and RT-nestRPA methods in example 3 of the present invention;
FIG. 6 is a graph showing the results of detection of RNA in a mock sample by RT-nestRPA double gene detection method in example 4 of the present invention;
FIG. 7 is a schematic diagram of grouping clinical samples of the novel coronary pneumonia according to example 5 of the present invention;
FIG. 8 is a graph showing the results of detecting N gene and RP gene in a sample of a physical examination of a double worker using RT-nestRPA in example 5 of the present invention;
FIG. 9 is a statistical chart of the results of testing clinical samples using RT-nestRPA and qPCR in example 5 of the present invention.
Detailed Description
The invention provides an RT-nestRPA concept, and develops an ultrahigh-sensitivity pathogen nucleic acid detection technology based on a fluorescence detection analyzer, so that the purpose gene and the reference gene of a pathogen can be simultaneously detected in the same tube, and the detection result can be more accurately interpreted. In the following examples of the present invention, a kit for detecting SARS-CoV-2 novel coronavirus, which can detect both SARS-CoV-2 virus N gene and human housekeeping gene RP gene, can detect SARS-CoV-2 nucleic acid fragment of 1 copy/uL under laboratory conditions, and has an ultrahigh sensitivity, is specifically described.
Compared with the traditional RPA and RT-RPA technologies, the RT-nestRPA technology adopted by the invention has the advantages that the RNA of a target gene and an internal reference gene can be detected in the same reaction tube, and the internal reference gene is utilized to carry out sample quality control. Meanwhile, the RT-nestRPA technology can quickly detect a sample to be detected with the concentration as low as 1 copy/uL, and accurately and reliably judges a positive result and a negative result through obvious fluorescence value difference of amplification products in a short time (15min), so that the kit has the characteristics of high sensitivity, high specificity and high repeatability.
EXAMPLE 1 primer and Probe design and screening of SARS-CoV-2 New coronavirus N Gene
Through searching SARS-CoV-2 gene mutation information published by the national biological information library (CNCB), the mutation frequencies of all genes in the new coronavirus genome are relatively uniform on average and are in the range of 0.78-1% (figure 1). Among them, the nucleotide mutation number of ORF1 gene is 17396 (FIG. 1), which is the gene with the most mutation number in the genome of new coronavirus, and it is one of the important reasons for the poor detection effect of ORF1 gene in clinical application. The SARS-CoV-2 pseudovirus standard product RNA available in laboratory only contains nucleic acid sequences of ORF1, E and N genes, and the sequence structure of E gene is not suitable for designing RPA probe through sequence analysis, and the variation number of N gene is low, so that the invention is designed according to the RPA primer and probe design principle for N gene.
An appropriate primer sequence is an important circle for efficient amplification of RPA, and a probe is designed by firstly searching a sequence of N genes with continuous 3 thymines (T) and modifying the probe with FAM fluorescein. 10 pairs of primers (Table 1) were designed at different positions at both ends of the probe, respectively, to screen out the most efficient combinations of primers and probes. In the primer screening, the first forward primer (F) is paired with the first to tenth reverse primers (R), respectively. Then, the reverse primers are screened again, and the first reverse primer (R) is paired with the first to tenth forward primers (F), respectively. Through two rounds of primer screening, the optimal primer combination with the largest slope and the shortest peak time was found.
TABLE 1N Gene primer and Probe design
Taking the pseudovirus culture solution which is re-warmed and uniformly mixed at room temperature for the new corona pseudovirus RNA quality control product, extracting the pseudovirus RNA by using a column type extraction method, and dissolving the RNA by using non-enzyme water. Pseudoviral RNA was diluted 1X 10 by serial dilution5copy/uL, 1X 104copy/uL, 1X 103copy/uL, 500 copies/uL, 100 copies/uL, 10 copies/uL and 1 copy/uL. At 1 × 105The copy/uL pseudovirus RNA is used as a template, and the result of primary screening shows that the amplification efficiency of FN-1/RN-2, FN1-/RN-3, FN6/RN-5 and FN-6/RN-7 is higher. Further, the above primer sets were each at 1X 105copy/uL, 1X 104copy/uL, 1X 103Using the RNA of the pseudoviruses with copy/uL, 500 copy/uL, 100 copy/uL, 10 copy/uL and 1 copy/uL as templates, using an RT-RPA method, setting the reaction time to be 30 minutes, observing whether the difference of fluorescence values between a sample to be detected and a blank control (without enzyme water) has statistical significance or not, and judging that the standard is p<0.05 is positive, p>0.05 is negative, and the lowest RNA concentration at which the detection result is positive is taken as the sensitivity of the primer pair. The results showed that the primer pairs FN-6/RN-7 and FN-1/RN-2 had higher sensitivity (Table 2), with the lowest detection limit of 500 copies/uL (FIG. 2). However, compared with the current qPCR method, the sensitivity of the detection method has no obvious advantage.
TABLE 2 preferred primer pairs and Probe combinations for the N Gene
The RT-RPA reaction system is as follows: the kit comprises enzyme freeze-dried powder (comprising reverse transcriptase, an RNase inhibitor, a recombinase, a single-stranded DNA binding protein and polymerase), 25uL buffer solution V, 2.1uL N gene forward outer primer (10uM), 2.1uL N gene reverse outer primer (10uM), 0.6uL specific probe (10uM), 1uL sample to be detected and 2.5uL magnesium acetate (280 mM). The reaction started immediately upon addition of magnesium acetate to the reaction system.
Example 2 comparison of the detection Capacity of RT-nestRPA and RT-RPA for SARS-CoV-2 pseudoviral RNA
SARS-CoV-2 pseudovirus RNA quality control (containing ORF1, E and N gene), i.e. new coronaviruses culture solution, verifies the sensitivity of N gene optimized primer. Taking the pseudovirus culture solution which is re-warmed and uniformly mixed at room temperature, extracting pseudovirus RNA by using a column type extraction method, and dissolving in enzyme-free water. Sequentially diluting the pseudovirus RNA extract to 500 copies/uL, 100 copies/uL, 10 copies/uL and 1 copy/uL as templates, respectively using RT-nestRPA and RT-RPA methods to detect, setting the reaction time to 30 minutes, observing whether the difference of fluorescence values between a sample to be detected and a blank control (without enzyme water) has statistical significance, and judging whether the standard is that p <0.05 is positive, p >0.05 is negative, and taking the minimum detectable RNA concentration as the LOD of the method.
The RT-nestRPA method detects RNA samples with different concentrations, and the RT-nestRPA method is found to aim at the N gene of the new coronavirus, the lowest detectable pseudoviral RNA concentration is 1 copy/uL (figure 3 and table 3), and the RT-RPA method can only detect the pseudoviral RNA concentration of 500 copy/uL (figure 3 and table 3). RT-nestRPA can obviously improve the detection sensitivity of SARS-CoV-2 virus N gene.
TABLE 3 comparison of RT-nestRPA and RT-RPA methods for detecting SARS-CoV-2 pseudovirus N Gene
The invention relates to a method for detecting SARS-CoV-2 pseudovirus by RT-nestRPA (RT-nested RPA), which comprises the following steps:
the method comprises the following steps: using a pair of external primers of SARS-CoV-2 virus N gene to perform RT-RPA reaction on template RNA for one time, and pre-amplifying a first segment of target gene N gene;
step two: using a pair of internal primers of SARS-CoV-2 virus N gene, taking the amplified first segment of the target gene as a template, and carrying out one time of RPA reaction under the condition of adding signal probes of different markers of the N gene, thereby amplifying the second segment of the target gene N gene. And detecting the probe signals of different labels to obtain the detection result of the virus nucleic acid N gene.
The signal probes with different labels are probes with different signal labels, and are usually probes with different fluorescein labels, such as fluorescein labeled probes of FAM, HEX, Cy3, Cy5, VIC, and the like.
In the first step, the RT-RPA reaction system is as follows: lyophilized enzyme powder (including reverse transcriptase, RNase inhibitor, recombinase, single-stranded DNA binding protein and polymerase), 25uL buffer solution V, 2.1uL forward outer primer (10uM), 2.1uL reverse outer primer (10uM), 5uL sample to be tested, and 2.5uL magnesium acetate (280 mM). The reaction started immediately upon addition of magnesium acetate to the reaction system.
In the second step, the RPA reaction system is as follows: lyophilized enzyme powder (including recombinase, single-stranded DNA binding protein, polymerase and exonuclease), 25uL buffer VI, 2.1uL forward inner primer (10uM), 2.1uL reverse inner primer (10uM), 0.6uL probe (10uM), all pre-reaction products, 2.5uL magnesium acetate (280 mM). The reaction started immediately upon addition of magnesium acetate to the reaction system.
The RT-RPA reaction in the first step can be carried out at 37-42 ℃ for 5-20 min. The reaction temperature is preferably 39 ℃ and the reaction time is preferably 15 min.
The RPA reaction in the second step can be carried out at 37-42 ℃ for 1-30 min. The reaction temperature is preferably 39 ℃ and the reaction time is preferably 15 min.
And (3) observing in real time by using a constant-temperature fluorescent amplification instrument, wherein a typical exponential amplification curve can be seen within 15min of on-line detection, the slope of the curve is greater than 20, the difference value of the fluorescence value and the blank/negative control has obvious statistical difference (p is less than 0.05), the result is judged to be a positive result, and the detection result of the N gene of the new crown nucleic acid of the sample to be detected is positive.
Example 3 design and screening of primers and probes for reference RP Gene and sensitivity analysis of RT-nestRPA
Human Ribonuclease P (RP) gene was selected as an internal reference gene according to the CDC guidelines, probes were designed at sequence positions with 3 consecutive thymines (T) according to the gene sequence (NM-001104546.1), and the probes were modified with HEX fluorescein. 10 pairs of primers were designed at different positions on both ends of the probe to screen out the most efficient primer and probe combinations (Table 4). In the primer screening, the first forward primer (F) is paired with the first to tenth reverse primers (R), respectively. Then, the reverse primers are screened again, and the first reverse primer (R) is paired with the first to tenth forward primers (F), respectively. Through two rounds of primer screening, the optimal primer combination with the largest slope and the shortest peak time was found.
TABLE 4 RP Gene primer and Probe design
The method comprises the steps of utilizing healthy human peripheral blood samples collected in a laboratory (the sample is negative in the detection results of SARS-CoV-2 virus N gene and test strip serum IgG/IgM antibody through the nestRPA), obtaining blood cells through high-speed centrifugal separation at 3000rpm, and extracting total RNA through a column extraction method for screening RP gene primers and testing the lowest detection capability of preferred primers. The total RNA of the blood cells is diluted by 10 times, 100 times, 1000 times, 5000 times and 10000 times in turn by a 10-time gradient dilution method. And (3) observing whether the difference of the fluorescence degrees between the sample to be detected and the blank control has statistical significance by using an RT-RPA method at the 30-minute reaction end point, wherein the judgment standard is that p <0.05 is positive and p >0.05 is negative. Through screening, the primer pair RP-F7/RP-R10 and RP-F2/RP-R6 meet the position relation of an inner primer pair and an outer primer pair when the blood cell total RNA sample with the same concentration is detected, the slope value of an amplification curve is large (table 5 and figure 4), and the blood cell total RNA sample diluted by 100 times can be detected at the lowest (figure 5, left). By using the RT-nestRPA method, the RP gene can detect a total RNA sample of blood cells diluted by 5000 times, and the detection sensitivity of the RP gene is obviously improved (figure 5 right).
TABLE 5 preferred primer pairs and Probe combinations for RP genes
The invention relates to a method for detecting RP reference genes by RT-nestRPA (RT-nested RPA), which comprises the following steps:
the method comprises the following steps: carrying out RT-RPA reaction on template RNA by using a pair of external primers of the RP gene to pre-amplify a first segment of the RP gene of a target gene;
step two: using a pair of internal primers of SARS-CoV-2 virus RP gene, using the amplified first segment of target gene as template, and making one RPA reaction under the condition of adding signal probes of different labels of RP gene to amplify second segment of target RP gene. And obtaining the detection result of the internal reference RP gene by detecting probe signals of different labels.
The signal probes with different labels are probes with different signal labels, and are usually probes with different fluorescein labels, such as fluorescein labeled probes of FAM, HEX, Cy3, Cy5, VIC, and the like.
In the first step, the RT-RPA reaction system is as follows: lyophilized enzyme powder (including reverse transcriptase, RNase inhibitor, recombinase, single-stranded DNA binding protein and polymerase), 25uL buffer solution V, 2.1uL forward outer primer (10uM), 2.1uL reverse outer primer (10uM), 5uL sample to be tested, and 2.5uL magnesium acetate (280 mM). The reaction started immediately upon addition of magnesium acetate to the reaction system.
In the second step, the RPA reaction system is as follows: lyophilized enzyme powder (including recombinase, single-stranded DNA binding protein, polymerase and exonuclease), 25uL buffer VI, 2.1uL forward inner primer (10uM), 2.1uL reverse inner primer (10uM), 0.6uL probe (10uM), all pre-reaction products, 2.5uL magnesium acetate (280 mM). The reaction started immediately upon addition of magnesium acetate to the reaction system.
The RT-RPA reaction in the first step can be carried out at 37-42 ℃ for 5-20 min. The reaction temperature is preferably 39 ℃ and the reaction time is preferably 15 min.
The RPA reaction in the second step can be carried out at 37-42 ℃ for 1-30 min. The reaction temperature is preferably 39 ℃ and the reaction time is preferably 15 min.
And (3) observing in real time by using a constant-temperature fluorescent amplification instrument, wherein a typical exponential amplification curve can be seen within 15min of on-line detection, the slope of the curve is greater than 20, the difference value of the fluorescence value and the blank/negative control have obvious statistical difference (p is less than 0.05), the result is judged to be a positive result, and the result of the detection of the internal reference RP gene of the sample to be detected is positive.
Example 4 preparation of a sample simulating positive infection by SARS-CoV-2 Virus and RT-nestRPA double Gene detection results
The RPA or RT-RPA detection method usually can only detect one target gene in one reaction, and if the expression condition of the reference gene of a sample to be detected needs to be determined, another reaction tube is needed for detection. Considering the characteristic that SARS-CoV-2 virus is RNA virus, in order to simplify the experimental steps, reduce the detection cost and improve the detection sensitivity, the invention firstly proposes the concept of RT-nestRPA, and innovatively detects the N gene of SARS-CoV-2 virus and the RP gene of human housekeeping gene in the same reaction tube, directly aims at RNA samples, and rapidly detects the N gene and the internal reference RP gene of SARS-CoV-2 virus with high sensitivity, and the monitoring system comprises the RP gene of the internal reference gene to control the quality of the experimental process, thereby avoiding false negative results.
Because SARS-CoV-2 virus has extremely strong infectivity, the RNA quality control of SARS-CoV-2 virus (pseudovirus culture solution, containing N gene, Guangzhou Bangdong Biotechnology Co., Ltd.) is purchased for primer screening and sensitivity test of RT-nestRPA technology. Meanwhile, a healthy human peripheral blood sample is collected (the sample is negative through RT-nestRPA N gene detection and new crown IgG/IgM antibody detection results), blood cells are obtained through high-speed centrifugal separation at 3000rpm, and the two samples are mixed to simulate a nucleic acid composition structure (the sample simultaneously contains SARS-CoV-2 virus RNA and RP gene) conforming to a true SARS-CoV-2 virus infection positive sample. The simulated sample consists of pseudovirus culture solution and healthy human blood cells according to the ratio of 1: 1 volume ratio, and extracting the total RNA of the mixed sample by a column extraction method. Meanwhile, pseudovirus culture solution RNA and human blood cell RNA are respectively extracted for RT-nestRPA double-gene detection.
The RT-nestRPA double-gene detection comprises two steps:
the method comprises the following steps: in the same reaction tube, a pair of external primers of SARS-CoV-2 virus N gene and a pair of external primers of RP gene are used simultaneously to perform RT-RPA reaction on template RNA and pre-amplify the first segment of target gene N gene and RP gene simultaneously.
Step two: in a new reaction tube, a pair of internal primers of SARS-CoV-2 virus N gene and a pair of internal primers of RP gene are used simultaneously, the amplified first segment of target gene is used as template, and under the condition of simultaneously adding signal probes of different labels of N gene and RP gene an RPA reaction is made, and at the same time the second segments of target gene N gene and RP gene are amplified.
And detecting the probe signals of different labels to obtain the detection results of the virus nucleic acid and the reference gene.
The differently labeled signaling probes are probes with different signaling labels, typically probes with different fluorescein labels, such as FAM, HEX fluorescein labeled probes.
In the first step, the RT-RPA reaction system is as follows: the enzyme freeze-dried powder (including reverse transcriptase, RNase inhibitor, recombinase, single-stranded DNA binding protein and polymerase), 25uL buffer solution V, 1.0uL N gene forward outer primer (10uM), 1.0uL N gene reverse outer primer (10uM), 1.0uL RP gene forward outer primer (10uM), 1.0uL RP gene reverse outer primer (10uM), 5uL sample to be tested, and 2.5uL magnesium acetate (280 mM). The reaction started immediately upon addition of magnesium acetate to the reaction system.
In the second step, the RPA reaction system is as follows: lyophilized enzyme powder (including recombinase, single-stranded DNA binding protein, polymerase and exonuclease), 25uL buffer solution VI, 1.0uL N gene forward inner primer (10uM), 1.0uL N gene reverse inner primer (10uM), 1.0uL RP gene forward inner primer (10uM), 1.0uL RP gene reverse inner primer (10uM),0.3uL N gene probe (10uM),0.3uL RP gene probe (10uM), total pre-reaction product (about 37uL), 2.5uL magnesium acetate (280 mM). The reaction started immediately upon addition of magnesium acetate to the reaction system.
The RT-RPA reaction in the first step can be carried out at 37-42 ℃ for 5-20 min.
The reaction temperature is preferably 39 ℃ and the reaction time is preferably 15 min.
The RPA reaction in the second step can be carried out at 37-42 ℃ for 1-30 min.
The reaction temperature is preferably 39 ℃ and the reaction time is preferably 15 min.
And (3) observing in real time by using a constant-temperature fluorescent amplification instrument, wherein a typical exponential amplification curve can be seen within 15min of on-line detection, the slope of the curve is greater than 20, and the difference value of the fluorescence value and the blank/negative control has obvious statistical difference (p is less than 0.05), so that a positive result is obtained.
The RT-nestRPA technology is used for detecting the RNA of the simulated sample, the RNA of the pseudovirus and the total RNA of the blood cells, and the result of the detection of the N gene detection channel (FAM fluorescent signal) shows that the RNA of the simulated sample and the RNA of the pseudovirus present a typical amplification curve, while the total RNA of the blood cells does not show a remarkable amplification curve (figure 6, left). The results in the RP gene detection channel (HEX fluorescent signal) showed that the mock sample RNA and total blood cell RNA exhibited typical amplification curves, whereas no significant amplification curve was seen for the pseudoviral RNA (fig. 6 right). The result shows that the RT-nestRPA double-gene detection system can not cause obvious fluorescent signal interference among different channels, and detectable cross reaction can not be generated among different primers.
When the typical exponential amplification curve is generated in the N gene detection channel and the internal reference RP gene detection channel of the sample to be detected simultaneously, the result of the nucleic acid detection of SARS-CoV-2 virus in the sample to be detected is judged to be positive. If the N gene detection channel of the sample to be detected does not have an obvious amplification curve and the internal reference RP gene detection channel has a typical exponential amplification curve, the result of detecting the SARS-CoV-2 virus nucleic acid of the sample to be detected is judged to be negative. If the N gene detection channel of the sample to be detected has an obvious amplification curve and the internal reference RP gene detection channel does not have a typical exponential amplification curve, the detection result of the sample to be detected is judged to be suspicious, and secondary detection is carried out if necessary.
Example 5 RT-nestRPA Co-detection of N Gene and RP Gene in clinical samples
All clinical samples were subjected to nucleic acid extraction (including DNA and RNA) using an automated nucleic acid extractor according to the procedures of the nucleic acid extraction kit (Huayin Biotech co., Shenzhen, China). All nucleic acid samples are detected by real-time quantitative PCR (qPCR) nucleic acid, and whether the samples are positive samples of SARS-CoV-2 infection is judged. During the period from 2 months 2020 to 4 months 2020, 111 samples (nasopharyngeal swabs or sputum) from 84 patients were collected in Shenzhen third people hospital. The results include 15 qPCR test positive samples from 15 patients with confirmed coronary pneumonia, 64 qPCR test negative samples from 37 patients with confirmed coronary pneumonia, and 32 samples from 32 patients with repeat work and healthy physical examination (fig. 7, the numerical values in fig. 7 are the number of cases).
RNA from clinical specimens was co-detected for both N and RP genes using RT-nestRPA as described in example 4. Clinical samples with positive qPCR (N gene and internal reference gene) detection results are detected by the RT-nestRPA method, and 1 of the clinical samples with positive qPCR (N gene and internal reference gene) detection results are continuously diluted by 11 times and 10 times. The serial dilution samples were then tested using the RT-nestRPA dual gene assay. Samples with negative qPCR (N gene) detection results were also tested using the RT-nestRPA double gene method of the invention.
15 nasal swabs or sputum samples from 15 patients with confirmed diagnosis of COVID-19, all positive for detection of SARS-CoV-2N gene using the qPCR method. The detection result of the RT-nestRPA method is consistent with the detection result of the N gene by the qPCR method, and the positive coincidence rate is 100 percent (15/15). Meanwhile, the RT-nestRPA method of the invention is used for detecting the reference genes (RP genes) of 15 samples, and the detection results are positive (Table 6).
TABLE 6 comparison of the results of the detection of the N gene and the reference gene of RT-nestRPA in the qPCR-positive samples
And selecting one positive sample, carrying out continuous 11 times of 10-fold ratio dilution, respectively using the RT-nestRPA and qPCR method to carry out synchronous detection, and comparing the sensitivities of the RT-nestRPA and the qPCR method. The results showed that the SARS-CoV-2 nucleic acid positive sample was still positive after 10 th serial dilution by using the RT-nestRPA method of the present invention, while the qPCR method was negative for the sample after 4 th dilution (Table 7).
TABLE 7 comparison of the results of N gene detection of a positive sample by RT-nestRPA and qPCR methods
64 nasal, anal or sputum samples from 37 COVID-19 confirmed patients were collected and all negative for SARS-CoV-2 nucleic acid using the qPCR method, and 29.69% (19/64) of the samples were found positive using the RT-nestRPA method of the invention (Table 8). The result shows that false negative exists in the result of using qPCR method to detect COVID-19 to diagnose SARS-CoV-2 nucleic acid in patient sample, and the detection sensitivity of using the RT-nestRPA method of the invention is superior to that of qPCR method.
TABLE 8 comparison of the results of detection of N gene and reference gene of RT-nestRPA in qPCR negative samples
In order to observe whether asymptomatic infectors positive for SARS-CoV-2 nucleic acid were present in the general healthy population, 32 throat swab samples of the persons in physical examination were collected, and all of the samples were negative for SARS-CoV-2 nucleic acid detection by the qPCR method. However, 3 samples (9.37%) were found to be positive in the test using the RT-nestRPA method of the present invention (Table 9), and the 3 samples were also positive in the test using the reference gene RP gene (FIG. 8). The result shows that the nucleic acid detection method of the RT-nestRPA has higher sensitivity than the qPCR method, and has important significance for early detection of asymptomatic infectors carrying SARS-CoV-2.
TABLE 9 detection results of RT-nestRPA in the N gene and reference gene of the sample of the repeat physical examination
The nucleic acid detection method of RT-nestRPA of the invention detects N gene of new coronavirus and RP gene of reference gene in 111 cases of clinical samples in total. The detection results of 15 qPCR positive samples by the RT-nestRPA method disclosed by the invention are positive (15/15), the consistency rate with the qPCR detection method is 100%, and the false negative rate is 0%. In addition, the RT-nestRPA method of the invention detects 22 samples (22.91%) with positive result of the new coronavirus N gene in 96 qPCR negative samples (FIG. 9). By combining the results, compared with the qPCR method, the method has higher sensitivity and better application prospect for early detection of new coronavirus infectors.
The above-mentioned embodiments only express the embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the present invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Sequence listing
<110> Huang Wan Qiu, Huang Jian
<120> kit for detecting pathogen RNA, animal or human gene RNA and application thereof
<160> 12
<170> PatentIn version 3.3
<210> 1
<211> 163
<212> DNA
<213> SARS-CoV-2 novel coronavirus (Severe acid respiratory syndrome coronavirus 2)
<400> 1
caaattggct actaccgaag agctaccaga cgaattcgtg gtggtgacgg taaaatgaaa 60
gatctcagtc caagatggta tttctactac ctaggaactg ggccagaagc tggacttccc 120
tatggtgcta acaaagacgg catcatatgg gttgcaactg agg 163
<210> 2
<211> 48
<212> DNA
<213> Artificial sequence (Artificial)
<220>
<221> misc_feature
<222> (31)..(31)
<223> n is i6FAMdT
<220>
<221> misc_feature
<222> (32)..(32)
<223> n is idSp
<220>
<221> misc_feature
<222> (33)..(33)
<223> n is iBHQ1dT
<400> 2
taaaatgaaa gatctcagtc caagatggta nnnctactac ctaggaac 48
<210> 3
<211> 35
<212> DNA
<213> Artificial sequence (Artificial)
<400> 3
caaattggct actaccgaag agctaccaga cgaat 35
<210> 4
<211> 35
<212> DNA
<213> Artificial sequence (Artificial)
<400> 4
cctcagttgc aacccatatg atgccgtctt tgtta 35
<210> 5
<211> 35
<212> DNA
<213> Artificial sequence (Artificial)
<400> 5
ccagacgaat tcgtggtggt gacggtaaaa tgaaa 35
<210> 6
<211> 35
<212> DNA
<213> Artificial sequence (Artificial)
<400> 6
gtctttgtta gcaccatagg gaagtccagc ttctg 35
<210> 7
<211> 198
<212> DNA
<213> Intelligent (Homo sapiens)
<400> 7
accttggcta ttcagttgtt gctatcaatc atatcgttga ctttaaggaa aagaaacagg 60
aaattgaaaa accagtagct gtttctgaac tcttcacaac tttgccaatt gtacagggaa 120
aatcaagacc aattaaaatt ttaactagat taacaattat tgtctcggat ccatctcact 180
gcaatgtttt gagagcaa 198
<210> 8
<211> 48
<212> DNA
<213> Artificial sequence (Artificial)
<220>
<221> misc_feature
<222> (31)..(31)
<223> n is iHEXdT
<220>
<221> misc_feature
<222> (32)..(32)
<223> n is idSp
<220>
<221> misc_feature
<222> (33)..(33)
<223> n is iBHQ1dT
<400> 8
accagtagct gtttctgaac tcttcacaac nnngccaatt gtacaggg 48
<210> 9
<211> 35
<212> DNA
<213> Artificial sequence (Artificial)
<400> 9
ttgttgctat caatcatatc gttgacttta aggaa 35
<210> 10
<211> 35
<212> DNA
<213> Artificial sequence (Artificial)
<400> 10
ttgctctcaa aacattgcag tgagatggat ccgag 35
<210> 11
<211> 35
<212> DNA
<213> Artificial sequence (Artificial)
<400> 11
ctttaaggaa aagaaacagg aaattgaaaa accag 35
<210> 12
<211> 35
<212> DNA
<213> Artificial sequence (Artificial)
<400> 12
tgagatggat ccgagacaat aattgttaat ctagt 35
Claims (20)
1. The kit for detecting the pathogen RNA and the animal or human gene RNA is characterized by comprising a primer pair for detecting the pathogen RNA and the animal or human gene RNA by using RT-nested RPA and a primer pair for detecting the internal reference gene RNA by using RT-nested RPA, wherein the primer pair for detecting the pathogen RNA and the animal or human gene RNA and the primer pair for detecting the internal reference gene RNA simultaneously carry out detection reaction in the same reaction tube.
2. The kit for detecting pathogen RNA and animal or human gene RNA according to claim 1, wherein the pathogen RNA comprises RNA of virus, bacteria, chlamydia, mycoplasma, rickettsia, spirochete, fungus, or parasite, and the animal or human gene RNA comprises mRNA of human tumor-related gene and mRNA of genetic disease-related gene.
3. The kit for detecting the RNA of a pathogen, or the RNA of an animal or human gene, according to claim 2, wherein the pathogen is SARS-CoV-2 neocoronavirus.
4. The kit for detecting pathogen RNA, or animal or human gene RNA, according to claim 3, wherein the primer pair for detecting SARS-CoV-2 new coronavirus RNA by RT-nested RPA is a primer pair directed to the nucleotide sequence of SEQ ID NO: 1 or a primer pair designed by the partial sequence of the N gene sequence of the SARS-CoV-2 new coronavirus.
5. The kit for detecting pathogen RNA, animal or human gene RNA according to claim 4, wherein the primer pair for detecting SARS-CoV-2 new coronavirus by RT-nested RPA comprises: SEQ ID NO: 3 and SEQ ID NO: 4, the sequence shown in SEQ ID NO: 5 and SEQ ID NO: 6.
6. The kit for detecting RNA of a pathogen, or RNA of an animal or human gene, according to claim 3, wherein the reference gene is the RP gene of the human housekeeping gene.
7. The kit for detecting RNA of a pathogen and RNA of an animal or human gene as claimed in claim 6, wherein the primer pair for detecting RP gene by nested RPA comprises: SEQ ID NO: 9 and SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12.
8. The kit for detecting pathogen RNA, and animal or human genetic RNA according to claim 3, further comprising a nucleic acid sequence specific for SEQ ID NO: 1 or partial sequence of N gene sequence of SARS-CoV-2 new coronavirus.
9. The kit for detecting pathogen RNA, or animal or human genetic RNA, according to claim 6, further comprising a nucleic acid sequence specific for SEQ ID NO: 7 or a partial sequence thereof.
10. A primer pair for detecting SARS-CoV-2 new coronavirus is a primer pair for detecting SARS-CoV-2 new coronavirus N gene by RT-nested RPA, and comprises an outer primer pair and an inner primer pair.
11. The primer pair for detecting SARS-CoV-2 novel coronavirus according to claim 10, wherein the primer pair is a primer pair directed to SEQ ID NO: 1 or a partial sequence thereof, wherein the outer primer pair has the sequence shown in SEQ ID NO: 3 and SEQ ID NO: 4, and the inner primer pair has a nucleotide sequence shown as SEQ ID NO: 5 and SEQ ID NO: 6 in a sequence listing.
12. A probe for detecting SARS-CoV-2 neo-coronavirus, wherein said probe is specific for SEQ ID NO: 1 or partial sequence of N gene sequence of SARS-CoV-2 new coronavirus.
13. The probe for detecting SARS-CoV-2 neo-coronavirus according to claim 12, wherein the probe has the sequence as shown in SEQ ID NO: 2, or a nucleotide sequence shown in the figure.
14. A kit for detecting SARS-CoV-2 neocoronavirus, comprising the primer pair of claim 10 or 11.
15. The kit for detecting SARS-CoV-2 novel coronavirus according to claim 14, wherein the kit further comprises a primer pair for detecting internal reference gene by RT-nested RPA, and the primer pair for detecting SARS-CoV-2 novel coronavirus N gene and the primer pair for detecting internal reference gene perform detection reaction simultaneously in the same reaction tube.
16. The kit for detecting SARS-CoV-2 neo-coronaviruses according to claim 15, further comprising the probe of claim 12 or 13, and a probe specific for an internal reference gene.
17. The kit for detecting SARS-CoV-2 neo-coronavirus according to claim 15 or 16, wherein the reference gene is a human housekeeping gene RP gene.
18. The kit for detecting SARS-CoV-2 neo-coronavirus according to claim 17, wherein the primer pair for detecting RP gene by RT-nested RPA comprises: SEQ ID NO: 9 and SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12.
19. The kit for detecting SARS-CoV-2 neo-coronavirus according to claim 17, wherein the probe for detecting the RP gene by RT-nested RPA is a probe specifically directed to the nucleotide sequence shown in SEQ ID NO: 7 or a partial sequence thereof, and has a sequence shown in SEQ ID NO: 8 in a nucleotide sequence shown in SEQ ID NO.
20. Use of a kit according to any one of claims 1 to 9 for the manufacture of a product for the detection of RNA from a pathogen.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2021/102134 WO2022266946A1 (en) | 2021-06-24 | 2021-06-24 | Kit for detection of pathogen rna and animal or human gene rna, and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113891944A true CN113891944A (en) | 2022-01-04 |
Family
ID=79016682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180001625.8A Pending CN113891944A (en) | 2021-06-24 | 2021-06-24 | Kit for detecting pathogen RNA, animal or human gene RNA and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113891944A (en) |
WO (1) | WO2022266946A1 (en) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2290096B1 (en) * | 2002-02-21 | 2014-11-19 | Alere San Diego, Inc. | Recombinase polymerase amplification using a temperature-sensitive recombinase agent |
WO2021212523A1 (en) * | 2020-04-25 | 2021-10-28 | Huang Wanqiu | Primer pair, probe and kit for detecting sars-cov-2 by means of using nested rpa technology and use thereof |
CN111500776A (en) * | 2020-04-29 | 2020-08-07 | 湖南润美基因科技有限公司 | Novel coronavirus 2019-nCoV fluorescent RPA detection primer, probe, kit and method |
CN111926117B (en) * | 2020-08-18 | 2022-09-13 | 交弘生物科技(上海)有限公司 | SARS-CoV-2 virus nucleic acid isothermal rapid detection kit and detection method |
CN112481358A (en) * | 2020-11-11 | 2021-03-12 | 清华大学 | Nested recombinase-polymerase amplification method and application thereof |
CN112553373A (en) * | 2020-12-08 | 2021-03-26 | 首都医科大学附属北京朝阳医院 | Kit and detection method for quickly detecting novel coronavirus 2019-nCoV nucleic acid |
CN112458210B (en) * | 2020-12-09 | 2021-12-10 | 上海伯杰医疗科技有限公司 | Gene conserved sequence, primer probe combination, kit and application for detecting new coronavirus |
CN112266986B (en) * | 2020-12-22 | 2021-03-16 | 博奥生物集团有限公司 | Virus nucleic acid extraction or preservation reagent, primer probe combination, virus amplification reagent, kit and application thereof |
-
2021
- 2021-06-24 WO PCT/CN2021/102134 patent/WO2022266946A1/en active Application Filing
- 2021-06-24 CN CN202180001625.8A patent/CN113891944A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2022266946A1 (en) | 2022-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111187856B (en) | Cpf1 kit for rapid detection of new coronavirus nucleic acid and preparation method and application thereof | |
CN110982943B (en) | Novel coronavirus RT-PCR detection method and kit | |
CN111235316B (en) | Primer probe for identifying novel coronavirus and application of primer probe in triple fluorescence RPA | |
CN111500776A (en) | Novel coronavirus 2019-nCoV fluorescent RPA detection primer, probe, kit and method | |
CN103397107B (en) | Bovine viral diarrhea virus (BVDV) fluorescent quantitative RT-PCR (reverse transcription-polymerase chain reaction) detection kit | |
WO2022179494A1 (en) | Salmonella typhi detection kit, preparation method therefor and application thereof | |
WO2021212523A1 (en) | Primer pair, probe and kit for detecting sars-cov-2 by means of using nested rpa technology and use thereof | |
CN108504778B (en) | Kit that is a kind of while detecting porcine circovirus 2 type and porcine pseudorabies virus and application | |
CN111286559B (en) | Primer, probe and kit for detecting African swine fever virus | |
CN108048584A (en) | The brucellar probe of RAA Fluorometric assays and kit | |
CN113652505B (en) | Method and kit for detecting novel coronavirus and VOC-202012/01 mutant strain thereof | |
CN112695134A (en) | Novel coronavirus COVID-19 nucleic acid detection primer group, probe group, detection kit and detection method | |
CN112662809A (en) | Nucleic acid composition for detecting novel coronavirus COVID-19 and application thereof | |
Gou et al. | The colorimetric isothermal multiple-self-matching-initiated amplification using cresol red for rapid and sensitive detection of porcine circovirus 3 | |
CN113046484B (en) | Primer probe, kit and method for detecting African swine fever virus p72 gene | |
CN111471800B (en) | Kit for detecting novel coronavirus and amplification primer composition thereof | |
CN112662808A (en) | Novel coronavirus COVID-19 nucleic acid detection kit and detection method thereof | |
CN112646927A (en) | Fluorescent RAA kit for detecting bovine sarcoidosis virus, detection method and application thereof | |
CN108676922A (en) | Primer and probe for detecting wild strain of porcine epidemic diarrhea virus and TaqMan real-time fluorescent quantitative PCR method | |
CN116121413A (en) | Real-time fluorescent nucleic acid isothermal amplification detection kit for group B streptococcus and special primer and probe thereof | |
CN113891944A (en) | Kit for detecting pathogen RNA, animal or human gene RNA and application thereof | |
CN112266980A (en) | Novel coronavirus 2019-nCoV real-time fluorescent PCR detection primer, probe, kit and method | |
CN113549709A (en) | Primer pair, probe and kit for detecting SARS-CoV-2 by utilizing nested RPA technology and application thereof | |
CN105567867A (en) | Human immunodeficiency virus 1 real-time fluorescent nucleic acid isothermal amplification detection kit | |
CN107022643A (en) | The 5p of miR 31 and miR 99a 5p distinguish the application in active tuberculosis and tuberculosis latent infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |